# Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

> **NCT02028767** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Empagliflozin 2.5 mg
- **DRUG:** Empagliflozin 10 mg
- **DRUG:** Metformin 500 mg
- **DRUG:** Empagliflozin/Metformin FDC

## Key facts

- **NCT ID:** NCT02028767
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02028767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02028767, "Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT02028767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*